Novartis announces clinical collaboration with Pfizer to advance the treatment of NASH
- Details
- Category: Novartis
Novartis announced today that it has entered into a clinical development agreement with Pfizer which will include a study combining tropifexor and one or more Pfizer compounds for the treatment of NASH, including an Acetyl CoA-Carboxylase (ACC) Inhibitor (PF-05221304, a Diacylglycerol O-Acyltransferase 2 (DGAT2) Inhibitor (PF-06865571, and a Ketohexokinase (KHK) Inhibitor (PF-06835919).
Roche announces FDA approval of Xofluza (baloxavir marboxil) for influenza
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the US Food and Drug Administration (FDA) has approved Xofluza™ (baloxavir marboxil) for the treatment of acute, uncomplicated influenza, or flu, in people 12 years of age and older. Xofluza is a first-in-class, single-dose oral medicine with a novel proposed mechanism of action that inhibits polymerase acidic endonuclease, an enzyme essential for viral replication.
AstraZeneca strengthens and expands oncology development and commercialisation collaboration with Innate Pharma
- Details
- Category: AstraZeneca
AstraZeneca, and its global biologics research and development arm MedImmune, announced a new multi-term agreement with Innate Pharma (Innate), building on an existing collaboration, aimed at accelerating each company's oncology portfolio and bringing new medicines to patients more quickly.
Alcon to develop SMART Suite digital health platform for cataract surgery
- Details
- Category: Novartis
Alcon, the global leader in eye care and a division of Novartis, today announced plans to develop the SMART Suite by Alcon, an innovative, digital platform that is designed to streamline, simplify and improve cataract surgery for surgeons and patients.
FDA approves asthma indication for Dupixent® (dupilumab)
- Details
- Category: Sanofi
The U.S. Food and Drug Administration has approved Dupixent® (dupilumab) as an add-on maintenance therapy in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid-dependent asthma.
Amgen invests £50 million ($66 Million) in Oxford Nanopore Technologies
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) and Oxford Nanopore Technologies Ltd. announced Amgen's equity investment of £50 million ($66 million) in Oxford Nanopore, a privately-owned, UK-based company advancing a new generation of portable, real-time genetic sequencing technology.
US FDA grants Lynparza Orphan Drug Designation for pancreatic cancer
- Details
- Category: AstraZeneca
AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) announced that they were granted orphan drug designation (ODD) by the US Food and Drug Administration (FDA) for Lynparza (olaparib) for the treatment of pancreatic cancer.
More Pharma News ...
- Amgen launches AMGEVITATM (biosimilar adalimumab) in markets across Europe
- Novartis 5-year data in psoriatic arthritis and ankylosing spondylitis reinforces Cosentyx® leadership in spondyloarthritis
- Boehringer Ingelheim increases awareness of health with the micro enterprise project 'Elephants' in South India
- Abbott names Robert B. Ford president, chief operating officer
- Sandoz announces global resolution of biosimilar adalimumab patent disputes, securing patient access
- Bristol-Myers Squibb and Compugen announce clinical collaboration to evaluate therapeutic regimen in advanced solid tumors
- Up to 10-years of follow-up data reaffirm safety profile of Mavenclad (cladribine tablets)